poisar

Stocks · News reference

Savara Says MOLBREEVI MAAs Under Review By EMA And U.K's MHRA; Decisions Expected Q1 2027 And Q4 2026, Respectively; European And Australian Patent Offices Grant MOLBREEVI Patents Until March 2041

Benzinga Newsdesk

MOLBREEVI* BLA PDUFA Target Action Date Set for November 22, 2026MOLBREEVI MAAs Under Review by the EMA and the U.K.’s MHRA; Decisions Expected in Q1 2027 and Q4 2026, respectivelyData Presented at ATS Showed

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

SVRA
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Benzinga Newsdesk

    Savara Q2 EPS $(0.16) Misses $(0.14) Estimate

    Savara (NASDAQ:SVRA) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 14.29 percent decrease over losses of $(0.14) per share from the

    SVRA